<DOC>
	<DOCNO>NCT00916279</DOCNO>
	<brief_summary>The study enroll patient angiographic evidence in-stent restenosis previously place bare-metal stent . Subjects treat Lutonix Catheter . The purpose investigate feasibility , safety , efficacy Lutonix Catheter native coronary system . Angiographic clinical outcome assess .</brief_summary>
	<brief_title>PERVIDEO I Registry , The Lutonix Paclitaxel-Coated Balloon Catheter Treatment Coronary In-Stent Restenosis</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male nonpregnant/nonbreast feed Female ≥18 Years age . Women childbearing potential must negative pregnancy test within 7 day procedure ; Documented stable angina pectoris Canadian Cardiovascular Society Classification ( CCSC ) 14 , unstable angina pectoris document ischemia ( Braunwald III ) document silent ischemia ; Previous history native coronary bare metal stenting ≥60 day ; LVEF ≥25 % ; Patient acceptable candidate PTCA , stenting , emergent CABG ; Patient willing provide inform consent comply followup visit test schedule ; Target lesion native coronary previous single bare metal stent ; Stenosis ≥50 % &lt; 100 % visual estimate QCA prior define predilatation ; Reference Vessel Diameter ( RVD ) ≥2.5 ≤3.25 ; Target lesion ≤40 mm length treat entirety 2 contiguous Lutonix Catheters ; Guidewire able cross lesion ( ) place distal vessel prior enrollment ; Enrollment permit successful treatment 1 2 nonstudy lesion single nonstudy vessel . Successful treatment define ≤30 % residual stenosis TIMI III flow evidence dissection . History Stroke within past 6 month ; History MI thrombolysis within 72 hour randomization ; History previous target vessel perforation ; Prior vascular brachytherapy ; Angiographic evidence thrombus dissection within target vessel ; Intervention another coronary lesion &lt; 60 day index procedure day plan follow index procedure ; Target lesion Left Main vessel ostium excessive calcification tortuosity involve bifurcation disease vessel ≥2.5 mm ; Target lesion plan treated something PTCA ( i.e . stent , cut balloon , atherectomy , VBT , etc . ) ; Uncontrollable allergy procedure medication , material , contrast ; Patient previous stent procedure drugcoated drug elute stent device target coronary vessel ; Known sensitivity paclitaxel antimitogenic agent ; Patient stent sandwich ( stench previously deploy within another stent ; Preprocedure CKMB &gt; 2x ULN positive Troponin ; Creatinine &gt; 2.0 mg/dl ; Leukocyte &lt; 3500/mL ; Platelet &lt; 100,000 mL &gt; 750,000 mL ; Currently take must resume warfarin ; Patient contraindicate antiplatelet therapy need withdrawn plan procedure ; The patient currently participate another investigational drug device study complete primary endpoint clinically interfere endpoint study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bare Metal In-Stent Restenosis</keyword>
	<keyword>Paclitaxel Coated Balloon Catheter</keyword>
	<keyword>Drug Coated Balloon</keyword>
	<keyword>Coronary Artery Disease</keyword>
</DOC>